Why Your GLP-1 Stopped Working: Weight-Loss Plateaus in Women, Explained
A plateau usually doesn't mean the drug has stopped working. It often means your body has reached a new balance point. Here is how to tell the difference, and what is worth checking before you change anything.
Most GLP-1 "stalls" are not the drug failing. As you lose weight, your body needs less energy, appetite-regulating hormones push back, and weight loss naturally slows until it levels off at a new set point. In the big trials of semaglutide and tirzepatide, the weight-loss curves dropped steeply in the first months and then flattened. If you've stalled, the useful questions are: are you still in the dose-escalation phase, has something else changed (sleep, protein, alcohol, a new medication, perimenopause), and has your body composition improved even if the scale hasn't moved? Then take that list to your prescriber.
Why plateaus happen
Your body needs less fuel at a lower weight
A smaller body burns fewer calories at rest and during movement. The same eating pattern that produced steady loss at your starting weight eventually just maintains your new weight. This is arithmetic, not a malfunction.
Your body defends against weight loss
After weight loss, appetite signals tend to increase and energy use can drop a little more than size alone would predict. GLP-1 drugs blunt the appetite side of this, which is why they work so well, but they don't erase it.
The trials show the same shape
In SURMOUNT-1, adults on tirzepatide lost roughly 15% to 21% of body weight on average over 72 weeks, compared with 3.1% on placebo. The Wegovy prescribing information and the Zepbound prescribing information both show weight change over time in their clinical studies sections: steep early, then leveling. Averages hide a wide range. Some people lose far more than the average, and some lose much less on the same dose.
The troubleshooting checklist
Work through these before deciding the medication has stopped working. Most are things to raise with your prescriber, not things to fix alone.
1. Where are you in the dose schedule?
GLP-1s start low and step up over months to reduce side effects. If you're still on an early dose, a slower phase is common. If you've reached your maintenance dose, a slowdown is also normal. Either way, the dose is your prescriber's decision. Dosing for prescription peptides is set by the prescribing clinician. Our GLP-1 dosing overview for women explains how titration works in general terms.
2. Are doses being missed or delayed?
Weekly injections get skipped during travel, illness or a busy month. Pills have rules of their own (some need an empty stomach and a wait before eating). Be honest in your log. A few missed doses can change appetite more than you'd expect, and labels give specific instructions for what to do after missed doses.
3. Is your medication what you think it is?
Brand-name products have tightly controlled strength. Compounded semaglutide and tirzepatide are not FDA-approved, and their potency and quality depend on the pharmacy. If you switched pharmacies or products and stalled at the same time, mention it. "Research use only" products are not sold for human use and have no quality standard you can rely on.
4. How much protein, and are you strength training?
Low protein and no resistance training make it more likely you lose muscle along with fat. Less muscle means a lower energy requirement, which can contribute to a stall, and it matters for strength and bone health. See our guide to GLP-1 muscle loss in women.
5. Have "liquid calories" crept back in?
GLP-1s are good at reducing hunger for meals, less so for sipping. Sweetened coffee drinks, juice, smoothies and alcohol can add up without triggering fullness. Alcohol also affects sleep and next-day food choices.
6. How are you sleeping?
Short or broken sleep is linked to increased appetite and cravings. Night sweats and insomnia in perimenopause are a common reason women's sleep falls apart mid-treatment.
7. Could perimenopause or menopause be a factor?
The menopause transition shifts fat toward the abdomen and makes it easier to lose muscle. Women in their 40s and 50s often describe a plateau that coincides with irregular periods, hot flashes or poor sleep. Hormone therapy is a separate decision with its own benefits and risks; our guide to HRT and peptides covers how the two areas overlap, and menopause belly fat explains why midsection fat behaves differently.
8. Has anything else changed medically?
New medications (some antidepressants, steroids, certain diabetes drugs and others are associated with weight gain), an underactive thyroid, or other health changes can slow loss. Bring a current medication list.
9. Is it a true plateau, or a fluid fluctuation?
Weight can swing day to day with salt, carbohydrate intake, constipation and the menstrual cycle. Many women retain water in the days before a period. Look at the trend over three to four weeks, ideally at the same point in your cycle, before calling it a plateau.
10. What does your body composition say?
If you've started strength training, you may be losing fat and keeping or building some muscle while the scale holds steady. Waist measurements, how clothes fit, strength gains and (if available) body composition scans can show progress the scale misses.
Plateau log: bring this to your appointment
| Item | What to note |
|---|---|
| Weight trend | 4 weeks of readings, same time of day, cycle day if you have periods |
| Medication | Product, pharmacy, dose, any missed or late doses |
| Food | Rough protein per day, drinks with calories, alcohol |
| Activity | Strength sessions per week, daily steps if you track them |
| Sleep | Average hours; night waking, night sweats |
| Symptoms | Cycle changes, hot flashes, fatigue, constipation |
| Other measures | Waist, clothing fit, strength changes |
Questions to ask your prescriber
- Is this a normal leveling-off for my dose and time on treatment, or a sign something's changed?
- Is there room to adjust the dose, or are we at the maximum for this medication?
- Would a different medication be worth considering? (Our semaglutide vs tirzepatide comparison lays out how the two differ.)
- Should we check thyroid function or other labs?
- Could any of my other medications be working against weight loss?
- Given my age and symptoms, should we talk about perimenopause or menopause care?
- What's a realistic goal for maintaining the weight I've already lost?
What not to do
- Don't raise your own dose or double up. Higher doses increase GI side effects and other risks, and the decision belongs with your prescriber.
- Don't add unapproved "stacks." Plateaus are a common moment for people to add research peptides marketed for fat loss. These are not sold for human use and have no approved human dose. For the approved options and how the rest compare on evidence, see our weight management hub.
- Don't slash food intake. Eating very little on top of a GLP-1 can speed muscle loss, worsen hair shedding and leave you short on nutrients.
Maintenance is a win, not a failure
If you've lost a meaningful amount of weight and your health markers have improved, holding steady at that new weight is the goal of long-term treatment. The trials of people who stopped treatment show that weight tends to return after stopping, which is why many clinicians treat obesity as a long-term condition. A plateau at a healthier weight, with your muscle intact, is what success looks like after the early months.
If you have a condition like lipedema, where certain fat responds poorly to weight loss in general, a plateau may also reflect that. See lipedema and GLP-1s.
Prescription Option (Telehealth)
If you're managing GLP-1 treatment through telehealth, choose a service where you can reach a clinician to review a plateau, side effects and dose decisions.
BiltRx offers GLP-1 care through telehealth. A licensed clinician decides whether a medication is appropriate for you. Compounded semaglutide and compounded tirzepatide are not FDA-approved.
Sources
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
- Novo Nordisk. Wegovy (semaglutide) prescribing information.
- Eli Lilly. Zepbound (tirzepatide) prescribing information.